<DOC>
	<DOCNO>NCT01950247</DOCNO>
	<brief_summary>The main objective study compare safety , effect quality life , resource utilization Injectafer vs. intravenous ( IV ) iron standard care ( SOC ) treatment iron deficiency anemia ( IDA ) infusion center set . The study also assess ability baseline serum hepcidin level predict subject clinically meaningful hemoglobin response oral iron therapy IV iron therapy .</brief_summary>
	<brief_title>Trial Evaluate Utility Serum Hepcidin Levels Predict Response Oral IV Iron Compare Safety , Effect Quality Life , Resource Utilization Injectafer vs Intravenous Standard Care Treatment IDA Infusion Center Setting</brief_title>
	<detailed_description>The main objective study compare safety , effect quality life , resource utilization Injectafer vs. intravenous ( IV ) iron standard care ( SOC ) treatment iron deficiency anemia ( IDA ) infusion center set . The study also assess ability baseline serum hepcidin level predict subject clinically meaningful hemoglobin response oral iron therapy 28 day IV iron therapy .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Hepcidins</mesh_term>
	<criteria>Male female subject â‰¥ 18 year age able give inform consent . Iron deficiency primary etiology anemia . If use erythropoiesis stimulating agent ( ESA ) , subject must use dose consistent package insert stable least 30 day . Doses potential myelosuppressive medication stable least 30 day . Females risk pregnancy must agree use acceptable form birth control negative serum urine pregnancy test first day dose . Hypersensitivity reaction component Injectafer . Requires dialysis treatment chronic kidney disease ( CKD ) . No evidence iron deficiency . During 10 day period prior screen treat intravenous iron . During 30 day period prior screen treat red red blood cell transfusion . Any nonviral infection . Known positive hepatitis evidence active disease . Received investigational drug within 30 day screen . Alcohol drug abuse within past 6 month . Hemochromatosis iron storage disorder . Estimated life expectancy le 6 month , cancer patient , ECOG Performance Status great 1 . Pregnant actively try become pregnant ( definitive negative result serum urine pregnancy test perform first day dosing require study enrollment woman childbearing potential ) . Any laboratory abnormality , medical condition psychiatric disorder opinion investigator would put subject 's disease management risk may result subject unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>